scholarly article | Q13442814 |
P2093 | author name string | Andrew M Davidoff | |
Amit C Nathwani | |||
Catherine Y C Ng | |||
Junfang Zhou | |||
Yunyu Spence | |||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 480-488 | |
P577 | publication date | 2003-03-13 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway | |
P478 | volume | 102 |
Q54210504 | A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. |
Q40297453 | AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice. |
Q36084471 | AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivo |
Q35733790 | AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage. |
Q36106403 | AAV9 supports wide-scale transduction of the CNS and TDP-43 disease modeling in adult rats |
Q59351936 | Adeno-associated viral gene therapy corrects a mouse model of argininosuccinic aciduria |
Q45367165 | Adeno-associated virus serotype 9-mediated pulmonary transgene expression: effect of mouse strain, animal gender and lung inflammation |
Q45422040 | Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer |
Q82970751 | Age-related efficacy with an AAV vector in Fabry disease mice |
Q35184237 | Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease |
Q42176546 | Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy |
Q45401411 | Biodistribution and tumor infectivity of semliki forest virus vectors in mice: effects of re-administration. |
Q35184180 | Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery |
Q38383086 | Clinical therapeutics for phenylketonuria |
Q33832790 | Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria |
Q43545330 | Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes. |
Q40418515 | Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models |
Q92464614 | Comparisons of Infant and Adult Mice Reveal Age Effects for Liver Depot Gene Therapy in Pompe Disease |
Q87942816 | Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model |
Q33617709 | Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria. |
Q45369054 | Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector |
Q64377006 | Conditional disruption of hepatic carbamoyl phosphate synthetase 1 in mice results in hyperammonemia without orotic aciduria and can be corrected by liver-directed gene therapy |
Q59354463 | Determining the Minimally Effective Dose of a Clinical Candidate AAV Vector in a Mouse Model of Crigler-Najjar Syndrome |
Q40483404 | Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. |
Q89777435 | Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors |
Q37042394 | Enhancing transduction of the liver by adeno-associated viral vectors |
Q97423848 | Experimental Variables that Affect Human Hepatocyte AAV Transduction in Liver Chimeric Mice |
Q90512896 | FVIII activity following FVIII protein infusion or FVIII gene transfer predicts the bleeding risk in hemophilia A rats |
Q59355726 | Gene Therapy for C1 Esterase Inhibitor Deficiency in a Murine Model of Hereditary Angioedema |
Q47225946 | Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice |
Q36634890 | Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8. |
Q91972798 | Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model |
Q35568513 | Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector |
Q45422901 | High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses |
Q45446011 | IFN-alpha gene therapy for woodchuck hepatitis with adeno-associated virus: differences in duration of gene expression and antiviral activity using intraportal or intramuscular routes |
Q90259907 | Immunosuppression overcomes insulin- and vector-specific immune responses that limit efficacy of AAV2/8-mediated insulin gene therapy in NOD mice |
Q40219232 | In Utero Transfer of Adeno-Associated Viral Vectors Produces Long-Term Factor IX Levels in a Cynomolgus Macaque Model. |
Q36951279 | In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA. |
Q36094151 | Induction of hepatocellular carcinoma by in vivo gene targeting |
Q92983960 | Interleukin-17 Drives Interstitial Entrapment of Tissue Lipoproteins in Experimental Psoriasis |
Q34467839 | LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives |
Q42203199 | Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome |
Q91302378 | Liver Expression of a MiniATP7B Gene Results in Long-Term Restoration of Copper Homeostasis in a Wilson Disease Model in Mice |
Q35754176 | Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice |
Q30498316 | Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer |
Q44298504 | Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice |
Q45881969 | Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period |
Q35199291 | Long-term sex-biased correction of circulating propionic acidemia disease markers by adeno-associated virus vectors |
Q48555858 | Long-term sustained effect of liver-targeted AAV gene therapy for MNGIE. |
Q37717893 | Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction |
Q35034401 | Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier |
Q45867051 | Metabolic basis of sexual dimorphism in PKU mice after genome-targeted PAH gene therapy |
Q36873312 | Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype |
Q42539441 | Mouse gender influences brain transduction by intravascularly administered AAV9. |
Q38622440 | New and improved AAVenues: current status of hemophilia B gene therapy |
Q41347222 | Non-clinical Safety and Efficacy of an AAV2/8 Vector Administered Intravenously for Treatment of Mucopolysaccharidosis Type VI. |
Q92561933 | Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets |
Q40039645 | Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose |
Q36846505 | Optimized adeno-associated virus 8 produces hepatocyte-specific Cre-mediated recombination without toxicity or affecting liver regeneration. |
Q92345005 | Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease |
Q34994501 | Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer |
Q61811179 | Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome |
Q34589262 | Preclinical Evaluation of a Recombinant Adeno-Associated Virus Vector Expressing Human Alpha-1 Antitrypsin Made Using a Recombinant Herpes Simplex Virus Production Method |
Q55341740 | Preclinical methods for the evaluation of periodontal regeneration in vivo. |
Q37134964 | Preclinical safety evaluation of recombinant adeno-associated virus 2 vector encoding human tumor necrosis factor receptor-immunoglobulin Fc fusion gene |
Q41579770 | Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy |
Q37547441 | Promyelocytic leukemia protein is a cell-intrinsic factor inhibiting parvovirus DNA replication |
Q34343763 | Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application |
Q36966120 | Protective effect of recombinant adeno-associated virus 2/8-mediated gene therapy from the maternal hyperphenylalaninemia in offsprings of a mouse model of phenylketonuria |
Q47215544 | RFX1 and RFX3 Transcription Factors Interact with the D Sequence of Adeno-Associated Virus Inverted Terminal Repeat and Regulate AAV Transduction |
Q40084021 | Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler-Najjar Syndrome Type I. |
Q36466909 | Safety and biodistribution assessment of sc-rAAV2.5IL-1Ra administered via intra-articular injection in a mono-iodoacetate-induced osteoarthritis rat model |
Q91897582 | Salmeterol with Liver Depot Gene Therapy Enhances the Skeletal Muscle Response in Murine Pompe Disease |
Q34729878 | Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model |
Q35848563 | Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver |
Q27321583 | Sex-related differences in gene expression following Coxiella burnetii infection in mice: potential role of circadian rhythm |
Q33714005 | Sexually dimorphic patterns of episomal rAAV genome persistence in the adult mouse liver and correlation with hepatocellular proliferation |
Q90226271 | Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors |
Q90349121 | Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research |
Q94487328 | Split AAV-Mediated Gene Therapy Restores Ureagenesis in a Murine Model of Carbamoyl Phosphate Synthetase 1 Deficiency |
Q28546963 | Strategies to rescue the consequences of inducible arginase-1 deficiency in mice |
Q91652467 | Sustained Correction of a Murine Model of Phenylketonuria following a Single Intravenous Administration of AAVHSC15-PAH |
Q34556835 | Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice. |
Q27300989 | Systemic AAV9 gene transfer in adult GM1 gangliosidosis mice reduces lysosomal storage in CNS and extends lifespan |
Q35568510 | Systemic administration of AAV8-α-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression |
Q24631198 | Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system |
Q35659639 | Systemic gene transfer to skeletal muscle using reengineered AAV vectors |
Q33995832 | Targeting multiple angiogenic pathways for the treatment of neuroblastoma |
Q46851925 | Testosterone-dependent transgene expression in the liver of the CAG-lacZ transgenic rat. |
Q40361106 | The inhibitory effects of anticoagulation on in vivo gene transfer by adeno-associated viral or adenoviral vectors |
Q41532325 | Transient suppression of hepatocellular replication in the mouse liver following transduction with recombinant adeno-associated virus. |
Q57296597 | Treatment of a metabolic liver disease by in vivo genome base editing in adult mice |
Q91059831 | Urocortin 2 Gene Transfer Improves Heart Function in Aged Mice |
Q30541880 | Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy |
Search more.